Whitehawk Therapeutics
WHWK
42 hedge funds and large institutions have $34.3M invested in Whitehawk Therapeutics in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 10 increasing their positions, 9 reducing their positions, and 8 closing their positions.
77% more capital invested
Capital invested by funds: $19.4M → $34.3M (+$14.9M)
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
11% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 9
5% more funds holding
Funds holding: 40 → 42 (+2)
0.95% more ownership
Funds ownership: 2.8% → 3.74% (+0.95%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IC
Ikarian Capital
Dallas,
Texas
|
+$3.34M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$3.18M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$1.53M |
| 4 |
SAM
Scion Asset Management
Saratoga,
California
|
+$1.53M |
| 5 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$1.13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.51M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$245K |
| 3 |
VF
Virtu Financial
New York
|
-$136K |
| 4 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$86K |
| 5 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$44K |
WHWK Hedge Fund Activity: Q1 2021 in Review
42 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Whitehawk Therapeutics (WHWK) for Q1 2021, worth a combined $34.3M — up 77% from $19.4M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new WHWK positions and 8 closed out — a net gain of 2 holders — while 10 added to existing stakes and 9 trimmed.
The largest buyer was Ikarian Capital, adding an estimated $3.34M. The largest seller was Vanguard Group, cutting an estimated $1.51M.
- 42 institutional investors held Whitehawk Therapeutics (WHWK) as of Q1 2021, up from 40 in Q4 2020.
- Funds reported $34.3M of Whitehawk Therapeutics stock for Q1 2021, up 77% quarter-over-quarter.
- 10 funds opened new Whitehawk Therapeutics positions in Q1 2021 and 8 closed out, a net change of +2 holders.
- The largest Whitehawk Therapeutics buyer in Q1 2021 was Ikarian Capital, an estimated $3.34M added.
- The largest Whitehawk Therapeutics seller in Q1 2021 was Vanguard Group, an estimated $1.51M sold.
Based on aggregated 13F filings for Q1 2021.